Gilead Sciences is a highly cash-generative, mature biopharma business anchored by its dominant HIV franchise. While top-line growth is constrained by patent maturities and competition, immense free cash flow generation easily supports a robust dividend and strategic oncology acquisitions. Fair value range: low $103, high $163, with mid-point at $132.
Englische Quelle wird angezeigt, während wir übersetzen
Dieser Bericht wurde noch nicht übersetzt. Aktualisieren Sie in ein paar Minuten, sobald die Übersetzungswarteschlange aufgeholt hat.
§1 Zusammenfassung
Fairly valued with a synthesized target of $132.47 compared to a current price of $134.06.
Dominant but mature HIV franchise faces long-term growth constraints and patent expirations.
Immense free cash flow easily supports a robust dividend and ongoing strategic oncology investments.
Near-term multiple expansion requires significant commercial breakthroughs in the oncology pipeline.
Fair value
$132
Margin of safety
-1.2%
Confidence
88/100
Moat
6.5/10
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
$134.06Price
Low $102.5
Mid $132.47
High $163
Gilead Sciences is a highly cash-generative, mature biopharma business anchored by its dominant HIV franchise. While top-line growth is constrained by patent maturities and competition, immense free cash flow generation easily supports a robust dividend and strategic oncology acquisitions.
Reverse DCF for GILD (GILD) backs out the revenue or earnings growth rate the current share price implies, holding terminal value, margin, and discount-rate assumptions constant.
We compare the implied rate to our own forecast deceleration curve and to the historical five-year actual. When the implied rate exceeds the realistic ceiling, the price is pricing in optimism the business has not yet demonstrated.
Reverse DCF uses cost of equity (Ke), not WACC, to stay consistent with the EPS-based forward valuation models. Ke is derived from CAPM with adjusted beta; the strict and moderate variants are documented in the assumption ledger.
When the implied growth rate is below our forecast, the market is underpricing the business; when it is above, the market is overpricing. The reverse-DCF read is one of four lenses that feed the composite fair-value range and the rating band.
FAQ
GILD — frequently asked questions
Based on our latest analysis, GILD trades close to fair value. The current price is $134 versus a composite fair-value midpoint of $132 (range $103–$163), which implies roughly 1.2% downside to the midpoint.
Our composite fair-value range for GILD is $103–$163, with a midpoint of $132. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for GILD's archetype.
Our current rating for GILD is Hold with a confidence score of 88/100. Hold. The synthesized fair value of $132.47 aligns closely with the current market price of $134.06. Upside is limited without significant pipeline success, but downside is protected by a strong fundamental yield. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for GILD are: Biktarvy LOE Collapse; Oncology Pipeline Failure; Aggressive Pricing Reform. The single biggest risk is Biktarvy LOE Collapse: Rapid market share loss following the loss of exclusivity for Biktarvy without adequate replacement from the oncology pipeline.
Our current rating for GILD is Hold, issued with a confidence score of 88/100 and a moat score of 6.5/10. The rating reflects the composite fair-value range ($103–$163) versus the current price of $134.
GILD is classified as a mature-dividend stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for GILD.
